- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00135512
Study Of 323U66 SR In Major Depressive Disorder
30. august 2018 opdateret af: GlaxoSmithKline
An Open-Label, Multi-Center, Phase II Study Evaluating the Safety and Efficacy of 323U66 SR in Patients With Depression
This study was designed to evaluate the efficacy and safety in major depressive disorder patients.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
234
Fase
- Fase 2
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
- GSK Investigational Site
-
-
-
-
-
Fukuoka, Japan, 814-0180
- GSK Investigational Site
-
Hyogo, Japan, 651-1145
- GSK Investigational Site
-
Kanagawa, Japan, 228-0828
- GSK Investigational Site
-
Kumamoto, Japan, 861-8002
- GSK Investigational Site
-
Saitama, Japan, 332-0012
- GSK Investigational Site
-
Tokyo, Japan, 160-0023
- GSK Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 64 år (Voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion criteria:
- Met DSM-IV-TR criteria for major depressive disorder for their current episode for at least 8 weeks prior to screening visit.
- Must give a written informed consent. But if the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written informed consent.
- Must have rating scores as outlined.
Exclusion criteria:
- Current or past history of seizure disorder or brain injury.
- Current or past history of anorexia or bulimia nervosa.
- History of manic episode.
- Past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder.
- Diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria.
- Pregnant, possibly pregnant or lactating.
- Must not be suicidal.
- Blood pressure of SBP>160mmHg, DBP>100mmHg.
- History or complication of cancer or malignant tumour.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Week 8 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 8
|
The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms.
The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed).
Total score ranges from 0-60.
A higher score indicates more depressive symptoms.
MADRS Response was defined as a reduction in MADRS score from Baseline.
Change from Baseline in the total score was calculated as the value at Week 8 minus the value at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 8
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change From Baseline in the MADRS Total Score at Week 52 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 52
|
The MADRS is a semi-structured interview rating scale for depression that assesses 10 symptoms.
The scale is composed of 10 questions (1, apparent sadness; 2, reported sadness; 3, inner tension; 4, reduced sleep; 5, reduced appetite; 6, concentration difficulties; 7, lassitude; 8, inability to feel; 9, pessimistic thoughts; 10, suicidal thoughts) with a fixed 7 point scale (0, no depression; 60, severely depressed).
Total score ranges from 0-60.
A higher score indicates more depressive symptoms.
MADRS Response was defined as a reduction in MADRS score from Baseline.
Change from Baseline in the total score was calculated as the value at Week 52 minus the value at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 52
|
|
Change From Baseline in the Hamilton Depression Rating Scale (HAM-D; 17 Items) Total Score at Weeks 8 and 52 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 8, 52
|
Each item was rated on either a 3-point scale (0 to 2; 8 questions) or a 5-point scale (0 to 4; 9 questions), with higher scores indicating greater symptom severity.
The total score was calculated by summing the individual response scores.
Total score ranged from 0 to 52.
The following symptoms were rated on a 5-point scale (0-4): depressed mood, low self-esteem (guilt), suicidal thoughts, work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic), anxiety (somatic), and hypochondriasis (somatization).
The following symptoms were rated on a 3-point scale (0-2): insomnia (initial), insomnia (middle), insomnia (late), gastrointestinal symptoms (appetite), somatic symptoms (general), sexual disturbances, insight, and weight loss.
Change from Baseline in the total score was calculated as the score at Week 8 and 52 minus the score at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 8, 52
|
|
Percentage of Participants Who Were Clinical Global Impression Global Improvement (CGI-I) Responders at Weeks 8 and 52 in Observed Cases
Tidsramme: Week 8, 52
|
The CGI-I scale was used to rate improvement in the participant's condition (benefits) since Baseline using the following 7-point scale: 1: very much improved, 2: much improved, 3: minimally improved, 4: not changed, 5: minimally worse, 6: much worse and 7: very much worse.
A responder was defined as "very much improved" or "much improved".
|
Week 8, 52
|
|
Change From Baseline in CGI Severity of Illness (CGI-SI) at Weeks 8 and 52 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 8, 52
|
CGI-SI was assessed on an 8-grade scale: 0, not assessed; 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill and 7, among the most extremely ill.
Higher score indicated severely ill.
CGI-SI was assessed by the investigator.
The change from Baseline in CGI-SI score was calculated as the score at Weeks 8 and 52 minus the score at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 8, 52
|
|
Change From Baseline in the Sheehan Disability Scale (SDISS) Total Score at Weeks 8 and 52 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 8, 52
|
SDISS is a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in the participant's life are impaired by panic, anxiety, phobic, or depressive symptoms.
The participant rates the extent to which his or her (1) work, (2) social life or leisure activities, and (3) home life or family responsibilities were impaired by his or her symptoms on a 10-point visual analog scale.
To get a total score, 3 individual scores were added and the total score ranged from "0 = unimpaired" to "30 = highly impaired".
Higher scores indicate worsening.
The change from Baseline in SDISS total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 8, 52
|
|
Change From Baseline in the Motivation Energy Inventory Short Form (MEI-SF) Total Score at Weeks 8 and 52 in Observed Cases
Tidsramme: Baseline (Week 0) and Week 8, 52
|
The MEI-SF (18 questions) was used to measure the reductions in mental energy, physical energy and social motivation.
Minimal clinically important differences were estimated as 0.5 standard deviations or 7.5 points.
All items use either a 7-level (0 to 6) or 5-level (0 to 4) response scale; items with a 5-level response scale were rescaled to 7-levels and items were reverse-scored as necessary such that higher scores represent higher health-related quality of life (HRQoL) total score ranges from 0 to 108 points.
Recall period was past week prior to administration.
The change from Baseline in MEI-SF total score was calculated as the score at Weeks 8 and 52 minus the score at Baseline.
Baseline was defined as value at Week 0.
|
Baseline (Week 0) and Week 8, 52
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. december 2004
Primær færdiggørelse (Faktiske)
28. maj 2007
Studieafslutning (Faktiske)
28. maj 2007
Datoer for studieregistrering
Først indsendt
24. august 2005
Først indsendt, der opfyldte QC-kriterier
24. august 2005
Først opslået (Skøn)
26. august 2005
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. februar 2019
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
30. august 2018
Sidst verificeret
1. august 2018
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Adfærdsmæssige symptomer
- Psykiske lidelser
- Stemningsforstyrrelser
- Depression
- Depressiv lidelse
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Psykotropiske stoffer
- Neurotransmitter optagelseshæmmere
- Membrantransportmodulatorer
- Antidepressive midler
- Dopaminmidler
- Cytokrom P-450 enzymhæmmere
- Antidepressive midler, anden generation
- Cytokrom P-450 CYP2D6-hæmmere
- Dopaminoptagelseshæmmere
- Bupropion
Andre undersøgelses-id-numre
- AK1102364
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .